Advances in cancer research. v. 142 / edited by Kenneth D. Tew, Paul B. Fisher. -- Amsterdam : Academic Press, cc2019. – (63.85489/A244/v.142)

Contents

Contributors

1. Highly variant DNA methylation in normal tissues identifies a distinct subclass of cancer patients

    1. Introduction

    2. Identifying OMP

    3. OMP patients in TCGA

    4. Do OMP patients have CIMP tumors?

    5. Are there pan-cancer OMP CpGs?

    6. Do OMP patients constitute a distinct subgroup of cancer patients?

    7. Do OMP patients have distinct tumor epigenomes?

    8. Are OMP individuals prone to adverse outcomes?

    9. What are potential causes of OMP?

    10. Conclusion and future directions

    Conflict of interest

    References

2. Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylations

    1. Epithelial plasticity--Basics and implications in cancer development, progression and treatment resistance

    2. Cancer metabolism--Metabolic adaptations in cancer

    3. Glycobiology--An introduction to protein glycosylation and relevance to cancer

    4. The hexosamine biosynthesis pathway (HBP)--An emerging metabolic player in cancer

    5. Epithelial plasticity and glycosylations in cancer

    6. Associations between EMT and O-GlcNAcylation

    7. The EMT-HBP-O-GlcNAcylation axis--An important new pathway to promote the neoplastic phenotype

    8. Conclusion and future directions

    Acknowledgments

    Conflict of interest

    References

3. The second genome: Effects of the mitochondrial genome on cancer progression

    1. Mitochondrial evolution and genetic variation

    2. Mitochondria and cancer

    3. Studying direct mtDNA contributions to disease

    4. Concluding remarks and remaining questions

    Acknowledgments

    Conflict of interest

    References

4. Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumors

    1. Introduction

    2. Methodology

    3. Results

    4. Discussion

    5. Expert opinion

    Acknowledgments

    References

5. HVEM network signaling in cancer

    1. Introduction

    2. HVEM network interactions in the immune microenvironment

    3. Genetic lesions in TNFRSF14 in lymphoid cancers

    4. Genetic lesions in TNFRSF14 in non-lymphoid cancers

    5. HVEM functions within the tumor microenvironment

    6. Therapeutic targeting of the HVEM network in lymphoma and other tumors

    7. Concluding remarks

    Funding

    References

6. Pharmacology of ME-344, a novel cytotoxic isoflavone

    1. Introduction

    2. Mitochondria as drug target organelles in cancer

    3. Cell components targeted by ME-344

    4. Preclinical investigational new drug (IND) enabling studies for ME-344

    5. Clinical studies

    6. Conclusions and future perspectives

    Acknowledgments

    Conflict of interest

    References